October 8 2021

Site visit at Xbrane and Xspray

On Tuesday 5th October Pareto invited clients to a site visit at Xbrane Biopharma and Xspray Pharma. Pareto’s clients were given in-depth insight into the companies through interactive presentations, guided tours of the labs and lively discussions with management teams and our analysts on the unique differentiators of the companies. 

 

The lab at Xbrane Biopharma.

 
With regards to Xbrane Biopharma, topics of discussion included the recent EMA filing for the pre-filled syringe of Xbrane Biopharma’s ophthalmology biosimilar – an antibody that is injected into the eye – while a competitor has only managed to file for the glass vial so far.
 
During the Xspray Pharma session, a lot of room was given to the unique supercritical CO2 extraction based technology that the company managed to upscale, which enables improvement of a wide range of orally administered cancer drugs while circumventing certain secondary patents of the originators.

 

 

Pareto Securities' Healthcare team; Peter Östling, Healthcare Analyst, Jan-Erik Borg Healthcare Broker, Dan Akschuti, Healthcare Analyst and Ingeborg Magnusson, Corporate & Client Communication Manager. 

Updates